The Gray Lady treats Ma Bell to a largely laudatory article. Though slow to commercialize its bright ideas, says the New York Times, Bell Labs succeeds by supporting fundamental scientific research while its competitors slash basic R&D spending.
Such Exquisite Taste
The novel industry of consumer genetics is sequencing our sense of smell, writes the Washington Post.
CNET pulls out all the stops in its coverage of Microsoft’s latest release: Office XP. Though short on surprises (aside from “Clippy lives!”), the package features some interesting analysis.
Get Ben Affleck on the Phone
The U.S. is girding for space warfare, reports New Scientist. It’s easy to kill satellites, says the article, but no one’s figured out how to defend them, so expect the first battle to look like Pearl Harbor in space.
The Bread Also Rises
Is that lovin’ in the oven? Nope. It’s gluten, whose secret recipe is now known, researchers tell the Times.
They Said I Was Mad
In this month’s Scientific American a scientist explains why his giant robot fly is a good idea and not just nightmare fodder. Short answer: bugs still fly better than we do.
Last Week: The Best of the Rest
This startup wants to copy you into an embryo for organ harvesting
With plans to create realistic synthetic embryos, grown in jars, Renewal Bio is on a journey to the horizon of science and ethics.
VR is as good as psychedelics at helping people reach transcendence
On key metrics, a VR experience elicited a response indistinguishable from subjects who took medium doses of LSD or magic mushrooms.
This artist is dominating AI-generated art. And he’s not happy about it.
Greg Rutkowski is a more popular prompt than Picasso.
This nanoparticle could be the key to a universal covid vaccine
Ending the covid pandemic might well require a vaccine that protects against any new strains. Researchers may have found a strategy that will work.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.